Phase 2 Hearing Loss Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have noticed difficulty hearing in noisy environments, lasting at least 6 months before the screening appointment
- People who show a measurable difficulty understanding speech when there is background noise, in at least one ear
- People whose hearing test results fall within the normal range or show up to a moderately severe level of hearing loss
Who may not be able to join:
- People who currently have a hole or tear in their eardrum
- People who currently have an ear infection, whether recent or ongoing
- People whose hearing loss is caused by a genetic condition
- People with severe hearing loss, whether it affects both ears equally or unevenly
- People who are currently receiving any treatment known to damage hearing
- People who had a middle or outer ear infection that cleared up fewer than 7 days before the start of the trial
- People with a history of long-term inflammatory or infected ear disease, or a condition called cholesteatoma (a skin growth in the ear)
- People with a history of otosclerosis, suspected fluid leak in the inner ear, suspected damage to the inner ear membrane, or ear injury caused by pressure changes (confirm with trial site)
- People who have had any type of ear surgery in the past
- People whose hearing loss comes and goes over time
- People whose hearing loss is caused by a physical blockage or structural problem in the ear (known as conductive hearing loss)
- People with a history of Ménière's disease, autoimmune-related hearing loss, radiation-caused hearing loss, or a non-cancerous tumour on the hearing nerve (acoustic neuroma)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Safety and tolerability: incidence, nature, severity and causality of treatment emergent adverse events (TEAE) and (Serious) Adverse events (S)(AEs); Tolerability at the injection sites using a 1-5 scale Common Terminology Criteria for Adverse Events (CTCAE) for pain, erythema, swelling, induration, nodule and ulceration with 1 : normal and 5: worst possible symptom/sign; Number of participants with at least one clinically significant abnormal laboratory result; Number of Participants With Abnormal ECG Findings
Can't join this trial?
Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.